Consultant Clinical Oncologist


Dr Ayman Madi

Professional Profile:

Where qualified

I graduated from Damascus University- Faculty of Medicine in 2001. Subsequently I moved to the UK and attained the MRCP degree in 2006. I was a research fellow at Cardiff University 2007-2009- the title of my MD thesis was “Pharmacogenetics of Advanced Colorectal Cancer”. I did my training in medical oncology in Newcastle upon Tyne and completed this in 2013.

Clinical Involvement

In 2014 I started my first consultant position at Clatterbridge Cancer Centre in Liverpool where I was an honorary senior clinical lecturer at the University of Liverpool and the lead for acute oncology at the Royal Liverpool Hospital. I was the principal investigator for several clinical trials and presented the outcome of my research work and quality improvement projects at international conferences.

I have moved to the Royal Berkshire Hospital in 2022 and I am currently the research lead at Berkshire Cancer Centre. I treat patients with breast and colorectal cancers and see private patients at Spire Dunedin Hospital.


  1. Clinical Audit/Service Improvement project of the year award, Clatterbridge Cancer Centre, for a project titled “DPYD genotyping for patients who develop severe toxicities on 5FU/Capectabine based regimens, 2021
  2. Clinical Excellent Award Level 2, Clatterbridge Cancer Centre, 2019
  3. Clinical Excellent Award Level 1, Clatterbridge Cancer Centre, 2018
  4. Medical Directors Award for Clinical Teaching, Clatterbridge Cancer Centre, 2016
  5. Conquer Cancer Foundation of ASCO Merit Award: In recognition of my abstract “Comprehensive Pharmacogenetic Profiling of Advanced Colorectal Cancer”, 2013


I have 11 academic papers published in peer reviewed journals in relation to cancer management and many more published in abstract form.


I have accepted educational grants from pharmaceutical companies to fund attendance at international cancer conferences and have taken part in consultancy boards for which I have received honoraria. I have no financial interests in any pharmaceutical company.